摘要
目的:针对ER阳性表达的卵巢癌患者,从Src激酶的表达入手,寻找其影响卵巢癌内分泌治疗的因素,探索卵巢癌细胞内分泌治疗机制,为卵巢癌内分泌治疗寻找新的出路。方法:选择40例ER表达阳性的接受手术、术后辅助化疗的Ⅲ期上皮性卵巢癌患者,这些患者在术后同时接受了雌激素受体拮抗剂-氟维司琼的治疗。应用免疫组织化学方法检测卵巢癌组织中活化的Src激酶表达情况,随访卵巢癌患者术后病情发展情况,明确Src激酶活性与卵巢癌患者病情进展的相关性。结果:根据p-Src的表达状态将患者分为p-Src阳性组和阴性组,p-Src阳性组患者术后进展加快,生存时间缩短,p-Src阴性患者术后病情进展相对缓慢,生存时间较长。结论:p-Src明显促进了卵巢癌患者的术后进展,并且影响了雌激素受体拮抗剂氟维司琼治疗的疗效,可能与卵巢癌内分泌治疗效果差有关。
Objective：Our research will focus on the ovarian cancer with ER positive expression,start from the expression of Src kinase,locate the fact which inhibit the endocrine therapy,analyze the endocrine therapy mechanism for ovarian cancer cells,and find out a new solution for endocrine therapy on ovarian cancer.Methods：Based on 40 patients with ER positive expression,who got operation and treatment with fulvestrant,the Src kinase expression in ovarian cancer had been analyzed by immunohistochemical method,and the development of the state of the illness after operation were also under monitoring,the relationship between the Src kinase activity and the development of the state of the illness had been confirmed.Results：The patient with p-Src positive expression took the turn for the worse compared to that with p-Src negative expression.Conclusion：The p-Src accelerates the worse of the state of ovarian cancer obviously,and inhibits the curative effect of estrogen receptor antagonists fulvestrant,which should be related with the bad curative effect of endocrine therapy on ovarian cancer.
出处
《现代肿瘤医学》
CAS
2017年第22期3680-3683,共4页
Journal of Modern Oncology
基金
陕西省中医药管理局项目(编号:15-LC044)
作者简介
赵娟（1982-），女，陕西富县人，主治医师，博士在读，研究方向：妇科肿瘤。E-mail：zhaojuan1982567@163．com
【通讯作者】李龙（1977-），男，北京人，副主任医师，博士，研究方向：妇科肿瘤。E-mail：fuchanys@mail．xjtu．edu．cn
